NRSN Neurosense Therapeutics Ltd
Company Analysis
Latest News
🟢 Neurosense Therapeutics is trading 10.77% up today amid volatility after reverse stock split
Neurosense Therapeutics is trading 10.77% up now at $6.89, with gains appearing primarily technical and highly volatile after its 1-for-20 reverse stock...
🔴 Neurosense Therapeutics is trading 8.86% down today after its 1-for-20 reverse stock split took effect
Neurosense Therapeutics is trading 8.86% down now at $6.11 after its 1-for-20 reverse stock split became effective September 14, 2026. - Nasdaq confirmed the...
🔴 Neurosense Therapeutics is trading 10.47% down today after announcing a 1-for-20 reverse share split
Neurosense Therapeutics is trading 10.47% down now at $0.36, with its company-specific reverse split the clearest explanation for the decline. - The...
🔴 Neurosense Therapeutics is trading 7.78% down today after announcing a 1-for-20 reverse share split
Neurosense Therapeutics is trading at $0.37, down 7.78%, after announcing a 1-for-20 reverse share split on September 9, 2026. • The reverse split is likely...
🔴 Neurosense Therapeutics is trading 10.22% down in pre-market after announcing 1-for-20 reverse share split
Neurosense Therapeutics is trading 10.22% down in pre-market at $0.36 after announcing a 1-for-20 reverse share split on September 9, 2026. • The...
NeuroSense Slashes Its Share Count by 95% to Dodge Delisting — But Can a Stock Split Save a Company Running on Fumes?
Shares tumbled 10.2% to $0.36 after NeuroSense Therapeutics announced a 1-for-20 reverse stock split — a move that combines every 20 existing shares into one —...
🔴 Neurosense Therapeutics is trading 10.2% down in after-hours trading after announcing 1-for-20 reverse share split
Neurosense Therapeutics is trading 10.2% down now at $0.36 after announcing a 1-for-20 reverse share split. - It closed at $0.40 on September 9, 2026. - The...
🟢 Neurosense Therapeutics is trading 7.63% up today with no clear company-specific catalyst
Neurosense Therapeutics is trading 7.63% higher at $0.45 after rebounding from its September 8 close of $0.42, with no clear company-specific announcement...
🟢 Neurosense Therapeutics is trading 7.63% up in after-hours trading amid volatility following September 4 gain
Neurosense Therapeutics is trading 7.63% up at $0.45, apparently amid continued volatility following the September 4 gain, with no clear company-specific...
🔴 Neurosense Therapeutics is trading 11.00% down today with no clear company-specific announcement identified
Neurosense Therapeutics is trading at $0.45, down 11.00%, after no clear company-specific announcement was identified for September 8, 2026. - Available...
🔴 Neurosense Therapeutics is trading 7.85% down today with no clear company-specific catalyst identified
Neurosense Therapeutics is trading 7.85% down at $0.47 after no clear company-specific announcement was identified for September 8, 2026. - The stock gained...
🔴 Neurosense Therapeutics is trading 5.6% down in pre-market with no clear company-specific announcement identified
Neurosense Therapeutics is trading at $0.48 (-5.64%) after no clear company-specific announcement was identified for September 8, 2026. • Broader futures are...
🔴 Neurosense Therapeutics is trading 6.05% down in after-hours trading
Neurosense Therapeutics is trading 6.05% down at $0.48, with no clear company-specific announcement or earnings release explaining the after-hours decline. -...
🟢 Neurosense Therapeutics is trading 12.1% up today after HC Wainwright initiated coverage with $8.00 target
Neurosense Therapeutics is trading 12.1% up at $0.45 after HC Wainwright initiated coverage on September 3, 2026, with a Buy rating and an $8.00 price...
🟢 Neurosense Therapeutics is trading 9.56% up today after HC Wainwright initiated Buy-rated coverage
Neurosense Therapeutics is trading 9.56% up now at $0.44 after HC Wainwright initiated coverage on September 3, 2026, with a Buy rating and an $8.00 price...
🟢 Neurosense Therapeutics is trading 8.69% up today after HC Wainwright initiated Buy-rated coverage
Neurosense Therapeutics is trading 8.69% up now at $0.45 after HC Wainwright initiated coverage on September 3, 2026, with a Buy rating and an $8.00 price...
🟢 Neurosense Therapeutics is trading 12% up in pre-market after HC Wainwright initiated Buy-rated coverage
Neurosense Therapeutics is trading 11.93% up at $0.46 after HC Wainwright & Co. initiated coverage on September 3, 2026, with a Buy rating and an $8.00 price...
🟢 Neurosense Therapeutics Surges in Pre-Market on HC Wainwright & Co. 'Buy' Rating and Redesigned PrimeC ALS Strategy
- Neurosense Therapeutics is trading 7.32% up in pre-market at $0.44 following HC Wainwright & Co. initiating coverage with a 'Buy' rating and an $8.00 price...
NeuroSense Rewrites Its ALS Playbook on a Shoestring — But Can a $0.45 Stock Outrun a September Delisting Clock?
Shares of NeuroSense Therapeutics surged 7.1% to $0.45 after the micro-cap biotech unveiled a redesigned, three-pronged strategy to push its lead ALS drug...
🟢 Neurosense Therapeutics is trading 7.09% up today after an accelerated, capital-efficient PrimeC strategy for ALS
Neurosense Therapeutics is trading 7.09% up at $0.45 after its August 31 announcement of an accelerated, capital-efficient PrimeC development strategy for...